tetano
Editor, Senior Moderator
PLoS One
. 2024 May 6;19(5):e0302896.
doi: 10.1371/journal.pone.0302896. eCollection 2024. CT abnormalities 3 and 12 months after hospitalization for COVID-19 and association with disease severity: A prospective cohort study
Trond Mogens Aaløkken[SUP] 1 2 [/SUP], Haseem Ashraf[SUP] 2 3 [/SUP], Gunnar Einvik[SUP] 2 4 [/SUP], Tøri Vigeland Lerum[SUP] 2 5 [/SUP], Carin Meltzer[SUP] 6 [/SUP], Jezabel Rivero Rodriguez[SUP] 6 [/SUP], Ole Henning Skjønsberg[SUP] 2 5 [/SUP], Knut Stavem[SUP] 2 4 7 [/SUP]
Affiliations
Objectives: To investigate changes in chest CT between 3 and 12 months and associations with disease severity in patients hospitalized for COVID-19 during the first wave in 2020.
Materials and methods: Longitudinal cohort study of patients hospitalized for COVID-19 in 2020. Chest CT was performed 3 and 12 months after admission. CT images were evaluated using a CT severity score (CSS) (0-12 scale) and recoded to an abbreviated version (0-3 scale). We analyzed determinants of the abbreviated CSS with multivariable mixed effects ordinal regression.
Results: 242 patients completed CT at 3 months, and 124 (mean age 62.3±13.3, 78 men) also at 12 months. Between 3 and 12 months (n = 124) CSS (0-12 scale) for ground-glass opacities (GGO) decreased from median 3 (25th-75th percentile: 0-12) at 3 months to 0.5 (0-12) at 12 months (p<0.001), but increased for parenchymal bands (p<0.001). In multivariable analysis of GGO, the odds ratio for more severe abbreviated CSS (0-3 scale) at 12 months was 0.11 (95%CI 0.11 0.05 to 0.21, p<0.001) compared to 3 months, for WHO severity category 5-7 (high-flow oxygen/non-invasive ventilation/ventilator) versus 3 (non-oxygen use) 37.16 (1.18 to 43.47, p = 0.032), and for age ≥60 compared to <60 years 4.8 (1.33 to 17.6, p = 0.016). Mosaicism was reduced at 12 compared to 3 months, OR 0.33 (95%CI 0.16 to 0.66, p = 0.002).
Conclusions: GGO and mosaicism decreased, while parenchymal bands increased from 3 to 12 months. Persistent GGO were associated with initial COVID-19 severity and age ≥60 years.
. 2024 May 6;19(5):e0302896.
doi: 10.1371/journal.pone.0302896. eCollection 2024. CT abnormalities 3 and 12 months after hospitalization for COVID-19 and association with disease severity: A prospective cohort study
Trond Mogens Aaløkken[SUP] 1 2 [/SUP], Haseem Ashraf[SUP] 2 3 [/SUP], Gunnar Einvik[SUP] 2 4 [/SUP], Tøri Vigeland Lerum[SUP] 2 5 [/SUP], Carin Meltzer[SUP] 6 [/SUP], Jezabel Rivero Rodriguez[SUP] 6 [/SUP], Ole Henning Skjønsberg[SUP] 2 5 [/SUP], Knut Stavem[SUP] 2 4 7 [/SUP]
Affiliations
- PMID: 38709747
- DOI: 10.1371/journal.pone.0302896
Objectives: To investigate changes in chest CT between 3 and 12 months and associations with disease severity in patients hospitalized for COVID-19 during the first wave in 2020.
Materials and methods: Longitudinal cohort study of patients hospitalized for COVID-19 in 2020. Chest CT was performed 3 and 12 months after admission. CT images were evaluated using a CT severity score (CSS) (0-12 scale) and recoded to an abbreviated version (0-3 scale). We analyzed determinants of the abbreviated CSS with multivariable mixed effects ordinal regression.
Results: 242 patients completed CT at 3 months, and 124 (mean age 62.3±13.3, 78 men) also at 12 months. Between 3 and 12 months (n = 124) CSS (0-12 scale) for ground-glass opacities (GGO) decreased from median 3 (25th-75th percentile: 0-12) at 3 months to 0.5 (0-12) at 12 months (p<0.001), but increased for parenchymal bands (p<0.001). In multivariable analysis of GGO, the odds ratio for more severe abbreviated CSS (0-3 scale) at 12 months was 0.11 (95%CI 0.11 0.05 to 0.21, p<0.001) compared to 3 months, for WHO severity category 5-7 (high-flow oxygen/non-invasive ventilation/ventilator) versus 3 (non-oxygen use) 37.16 (1.18 to 43.47, p = 0.032), and for age ≥60 compared to <60 years 4.8 (1.33 to 17.6, p = 0.016). Mosaicism was reduced at 12 compared to 3 months, OR 0.33 (95%CI 0.16 to 0.66, p = 0.002).
Conclusions: GGO and mosaicism decreased, while parenchymal bands increased from 3 to 12 months. Persistent GGO were associated with initial COVID-19 severity and age ≥60 years.